A leading biotechnology company in Matrix Therapy
A new branch of Regenerative Medicine
We are a clinical-stage regenerative medical device company founded by leading biologists Prof Denis Barritault and Prof Jean-Pierre Caruelle. Through their pioneering work on growth factors (the discovery of FGF, HARP/PTN) they invented RGTA® Technology (ReGeneraTing Agents), a new therapeutic class in regenerative medicine. OTR3 currently markets three products :
- Cacipliq® for wound healing (CE marked medical devices)
- Clerapliq for corneal lesions in animals.
- Dermapliq for skin lesions in animals
The RGTA® Technology is patented worldwide.
OTR3 is committed to explore the full potential of the RGTA® Technology by developing new indications and innovative healthcare products. Our expansion relies on extensive cutting-edge research and development that will allow to bring significant benefits for a large number of patients.
OTR3 enlarges its portfolio of new products thanks to his capabilities to design new RGTA® molecules for the treatment of targeted diseases.
OTR3 commercializes its products through distribution partnerships or out- licensing.
To bring to market comprehensive regenerative solutions for the treatment of dermatological and neurological diseases with large unmet medical needs and feed the pipeline for futur indication.
OTR3’s management team includes industry veterans with a wealth of experience and a commitment to driving OTR3 forward as the leading developer of novel regenerative matrix therapies.
A steering board, composed of recognised professionals, assists OTR3’s team providing scientific, business and strategic advice.
Pr Dulce PAPY
Director CRRET (CNRS Laboratory)
C.E.O of Arteion
Fomer Chief Medical Officer of major pharmas and Medical Consultant
Dr Catherine CART-GRES
Chief Medical Officer, SOM Biotech
Regional Sales Manager SWIFT
Senior VP Aventis – Integration Officer Sanofi-Aventis
VP Scale NGO, VP Terrawatt Initiative